CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 334 enrolled
Drug / intervention
rosuvastatindrug
Likely dose
rosuvastatin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00473655
NCT00473655Phase 4Completed

A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients

AstraZeneca·interventional·Posted May 15, 2007·Updated Dec 16, 2010

In Brief

A Phase 4 clinical trial evaluating rosuvastatin for Hypertriglyceridemia and 4 related conditions. Completed, enrolled 334 participants across 3 sites.

Detailed Summary

The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 15, 2007
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.1 years ago

Interventions

rosuvastatindrug

10mg or 20mg